74° Mostly Cloudy

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
News
- Local News
- State News
Sports
- Local Sports
- Pro Sports
Lifestyle
- Local Entertainment
Multimedia
Community Choice
Features
Classifieds
- Place Ad
- Legal Notices
Public Notices
Obituaries
E-Edition

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

9.235 -0.205 (-2.17%)

Delayed Quote Updated: 12:49 PM EDT, Oct 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

23 24 Next >

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

September 09, 2024

From ImmunityBio, Inc.

Via Business Wire

Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

August 19, 2024

Via Benzinga

How Is The Market Feeling About ImmunityBio? ↗

May 17, 2024

Via Benzinga

Top 3 Health Care Stocks That Are Set To Fly This Quarter ↗

August 16, 2024

Via Benzinga

9 Health Care Stocks Whale Activity In Today's Session ↗

August 13, 2024

Via Benzinga

IBRX Stock Earnings: ImmunityBio Misses EPS, Misses Revenue for Q2 2024 ↗

August 12, 2024

IBRX stock results show that ImmunityBio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Via InvestorPlace

ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval

August 12, 2024

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer

August 06, 2024

From ImmunityBio, Inc.

Via Business Wire

IMMUNITYBIO INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc. - IBRX

July 26, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

7 Biotech Stocks to Keep on Your Clinical Radar ↗

July 23, 2024

Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs.

Via InvestorPlace

3 Top Cancer Treatment Stocks to Buy Now ↗

July 17, 2024

These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term.

Via InvestorPlace

China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio? ↗

June 23, 2024

Top performing mid-cap stocks last week: BILI (+23%), IBRX (+22%), SSL (+20%), OLLI (+15%), ITCI (+13%), AMKR (+12%), IRTC (+11%), RKLB (+11%), BFH (+10%), BRFS (+10%).

Via Benzinga

Why ImmunityBio Stock Is Trading Higher Thursday ↗

June 20, 2024

The company announced insurance coverage of ANKTIVA, a immunotherapy used to treat non-muscle invasive bladder cancer that was unresponsive to other specific treatments.

Via Benzinga

KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday ↗

June 20, 2024

Via Benzinga

Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

June 20, 2024

Via Benzinga

ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors

June 20, 2024

From ImmunityBio, Inc.

Via Business Wire

3 Short-Squeeze Stocks Outwitting the Pessimistic Predictions ↗

June 20, 2024

Don't be discouraged by the bears. Here are my three picks of short-squeeze stocks to buy for investors everywhere.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 11, 2024

Via Benzinga

ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update

June 07, 2024

From ImmunityBio, Inc.

Via Business Wire

These 3 Interesting Stocks Are Seeing Heavy Short Interest In June 2024 ↗

June 04, 2024

Economic slowdown meets short-selling speculations. Candidates for incoming market volatility are here.

Via Talk Markets

Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast

May 17, 2024

From ImmunityBio, Inc.

Via Business Wire

Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months ↗

May 13, 2024

In the last three months, IBRX outperformed NVDA by over 3x.

Via Talk Markets

IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q1 2024 ↗

May 10, 2024

IBRX stock results show that ImmunityBio missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

Via InvestorPlace

The 3 Best Bargain Stocks to Buy in May 2024 ↗

May 09, 2024

There are several types of bargain stocks for investors to consider. Here are the three best bargain stocks to buy now.

Via InvestorPlace

Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday ↗

May 07, 2024

Via Benzinga

ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®

May 07, 2024

From ImmunityBio, Inc.

Via Business Wire

Even Worse than Gamestop? 3 Meme Stocks That Are Screaming Sells ↗

May 06, 2024

Here are just a few of the top meme stocks to sell immediately. In fact, I wouldn't waste investment dollars on any.

Via InvestorPlace

Serum Institute of India Inks Large-Scale Supply Deal For BCG Use In ImmunityBio's Bladder Cancer Combo Therapy ↗

May 03, 2024

Unlocking global access to Bacillus Calmette-Guerin (BCG) for cancer therapy. ImmunityBio partners with Serum Institute to expand BCG supply. FDA-approved Anktiva plus BCG for bladder cancer.

Via Benzinga

Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday ↗

May 03, 2024

Via Benzinga

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types

May 02, 2024

From ImmunityBio, Inc.

Via Business Wire

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Multimedia
Local Events
Classifieds
Obituaries
Weather
Online Features

Services

About Us
Contact Us
Promote Your Event
Subscriber Services
Online Forms
Rack Locations

woonsocketcall.com
Address: 154 Main Street
Woonsocket, RI 02895
Phone: 401-762-3000
Email: notices@woonsocketcall.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

All News about ImmunityBio, Inc. - Common Stock

Sections

Services